Basaglar KwikPen

Basaglar KwikPen

insulin glargine


Eli Lilly


Concise Prescribing Info
Insulin glargine
DM in adults, adolescents & childn ≥2 yr.
Dosage/Direction for Use
Administer SC once daily at any time but at the same time each day. Dose & timing should be individually adjusted.
Special Precautions
Diabetic ketoacidosis, transferring to another type or brand, changes in strength, origin &/or method of manufacture of insulin, hypoglycemia, patients w/ significant stenosis of the coronary arteries or of the blood vessels supplying the brain, proliferative retinopathy, intercurrent illness requires intensified metabolic monitoring, in combination w/ pioglitazone in patients w/ risk factor for development of cardiac heart failure. Pregnancy.
Adverse Reactions
Hypoglycemia; lipohypertrophy, inj site reactions.
Drug Interactions
May enhance blood-glucose-lowering effect & increase susceptibility to hypoglycemia w/ oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, somatostatin analogues & sulphonamide antibiotics. May reduce blood-glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetics [eg, epinephrine (adrenaline), salbutamol, terbutaline], thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. May potentiate or weaken the blood-glucose lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. May reduce the signs of adrenergic counter-regulation w/ β-blockers, clonidine, guanethidine & reserpine.
ATC Classification
A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Basaglar KwikPen soln for inj 100 u/mL
(in KwikPen) 3 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in